Daclizumab

Study Type of data Exposure measurement Outcome assessment Adjustment
Gold, 2016 retrospective cohort Clinics visits occurred every 4 weeks for daclizumab administration and safety and tolerability assessments; during the extension studies, visits were every 4–12 weeks. Investigators were required to report pregnancies and the subsequent outcome. None

See the method used to produce these results